Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:info@kmdbioscience.com
Catalog Number | YR1481 |
---|---|
Product Name | Anti-Human IL23A Recombinant Antibody(Mirikizumab) |
Molecular Name | Mirikizumab |
Alias | Anti-IL23A Recombinant Antibody, Research Grade Mirikizumab |
CAS Number | 1884201-71-1 |
Target | IL23A[Homo sapiens] |
Isotype | IgG4 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Background | Mirikizumab (INN, development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis. This drug was developed by Eli Lilly and Co. As of 2018, mirikizumab is undergoing Phase III trials. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |